Predictive Oncology
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Predictive Oncology generated cash of -$13,189,390, which is less than the previous year. Cash used in financing activities reached the amount of $148,898 last year. Net change in cash is therefore -$13,342,863.
Cash Flow
| 2014 | -3.37M | -121.23K | 3.40M |
|---|---|---|---|
| 2015 | -7.48M | -60.56K | 12.38M |
| 2016 | -4.38M | -422.86K | 1.71M |
| 2017 | -4.45M | -1.65M | 5.11M |
| 2018 | -5.28M | -1.11M | 5.79M |
| 2019 | -8.73M | -599.08K | 9.32M |
| 2020 | -12.25M | -167.45K | 12.95M |
| 2021 | -12.20M | -10.60M | 50.34M |
| 2022 | -12.37M | -475.69K | 6.71M |
| 2023 | -13.18M | -302.37K | 148.89K |
POAI Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 22.07M | 28.20M | 678.33K | 150.83K | 162.15K | 766.18K | 1.76M | 4.85M | 16.38K | 101.95K |
Operating activities | ||||||||||
Net income | -13.98M | -25.73M | -19.65M | -25.88M | -19.39M | -10.08M | -7.74M | -6.52M | -4.79M | -6.83M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 739.31K | 1.31M | 1.34M | 1.02M | 704.88K | 147.62K | 71.56K | 82.35K | 78.56K | 63.04K |
Stock-based compensation expense | 0 | 522.43K | 921.13K | 1.17M | 2.73M | 0 | 4.04M | 886.60K | 871.87K | 835.42K |
| Deferred income tax benefit | 0 | 522.43K | 921.13K | 1.17M | 2.73M | 0 | 4.04M | 886.60K | 871.87K | 835.42K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -2.50K | 23K | -20.76K | 69.91K | 143.31K | -95.10K | -98.58K | -636 | 19.26K | 39.69K |
Inventories | -63.88K | -42.80K | -98.14K | -94.71K | 91.11K | 23.97K | 7.16K | -40.46K | 135.62K | -245.19K |
Accounts payable | 398.57K | -78.32K | -350.29K | -1.65M | 365.77K | 305.22K | -79.65K | -430.30K | -1.54M | 1.13M |
Cash generated by operating activities | -13.18M | -12.37M | -12.20M | -12.25M | -8.73M | -5.28M | -4.45M | -4.38M | -7.48M | -3.37M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | -3.08M | -850K | 0 | 0 |
Investments In Property Plant And Equipment | -276.35K | -475.69K | -962.32K | -360.77K | -26.60K | -232.00K | -55.27K | -44.74K | -60.56K | -121.23K |
Acquisitions Net | 0 | 0 | -9.59M | 193.32K | 248.10K | 0 | 0 | -11.98K | 0 | 0 |
Cash generated by investing activities | -302.37K | -475.69K | -10.60M | -167.45K | -599.08K | -1.11M | -1.65M | -422.86K | -60.56K | -121.23K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 6.74M | 51.19M | 11.88M | 5.64M | 2.95M | 3.81M | 1.71M | 13.05M | 157.08K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -1.51K | -27.65K | -11.52K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 150.40K | 0 | -4.16M | -1.28M | 1.53M | -2.18M | 0 | 0 | -683.07K | -305K |
Cash used in financing activities | 148.89K | 6.71M | 50.34M | 12.95M | 9.32M | 5.79M | 5.11M | 1.71M | 12.38M | 3.40M |
Net Change In Cash | -13.34M | -6.13M | 27.52M | 527.50K | -11.32K | -604.03K | -997.90K | -3.09M | 4.83M | -85.56K |
Cash at end of period | 8.72M | 22.07M | 28.20M | 678.33K | 150.83K | 162.15K | 766.18K | 1.76M | 4.85M | 16.38K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |